Relief Therapeutics EUA for Zyesami Expanding to More Countries

More countries including the Nation of Georgia have issued an Emergency Use Authorization (EUA) for intravenous aviptadil for the treatment of critical COVID-19. This bodes well for the NeuroRX and Relief partnership that’s global and is expecting to be active in the U.S. soon.

Its collaboration partner, NRx Pharmaceuticals, Inc. is actively pursuing EUAs in countries in Europe now before the U.S. EUA is expected to proceed. Ticker $NRXP goes up like clockwork on any news, while the majority of the bounty will fall to OTC stock ticker $RLFTF.

Interestingly Relief’s stock is relatively low compared to where you would expect a Covid-19 Delta treatment to be, in the grand scope of things.

It’s not clear if this is because its a Swiss company on the OTC or for other reasons.

NRx also reported that the first doses of aviptadil will arrive in the Nation of Georgia within 24 hours, and discussions are underway with the Ministry of Health to provide access to ZYESAMI(TM) to Georgians suffering with Critical COVID-19.

The reality on the global situation is more countries are likely to proceed with EUA since Delta is surging in many countries who aren’t vaccinated to a high degree.

Effective Covid-19 treatments that help protect lungs in hospitalizations and against long-Covid are really in demand. Long Covid-19 can reduce patients to effectively be disabled and even decrease their intelligence with “brain fog” among other symptoms. It’s not clear how grave long-covid will be on the global economy in terms of productivity at scale.

Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief’s lead drug candidate, RLF-100 TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. Zyesami, it’s commercial name, has turned out to be one of the most effective treatments for serious Covid-19 cases. You can see their website here.

As more countries get EUA for Zyesami it’s only a matter of time until major European countries and the U.S. and other countries in grave danger approve it like Indonesia, India, Russia, Brazil and others.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit . As for as stocks go, $RLFTF has had much lower volume than one would expect as $NRXP only is really a significant winner within the U.S. So it’s a bit baffling to be honest, as this is likely one of the most important treatment in the Delta surge and likely in the Lambda surge later on.

Click on the $RLFTF in the tags of this article to learn more about the company and how effective Zyesami is against severe Covid-19.

Similar Posts